Effect of the SCAR CLEARING GEL to treat Scars.

A Prospective, Double Arm, Comparative, Clinical Study To Evaluate The Efficacy And Safety Of GLAZE SCAR CLEARING GEL With Mederma Scar Gel In Patients With Recent Scars. - NIL

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2023/09/058063

Enrollment

Registered

2023-09-26

Start date

Unknown

Completion date

Unknown

Last updated

2024-01-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L905- Scar conditions and fibrosis of skin

Interventions

Intervention1: GLAZE SCAR CLEARING GEL: Dimethicone and Dimethicone/Vinyl Dimethicone Crosspolymer IH 80.00%(W/W) Propylene Glycol Monocaprylate IH 4.00% (w/w) L-ascorbic Acid IH/IP 5.00 % (w/w) Aloe

Eligibility

Inclusion criteria

Inclusion criteria: 1. Healthy male and female subjects in the age group of 18-50 years 2. Subject having visible recent scars (Face region) because of any trauma, acne, dermatitis, Accidental scar, Surgery Scar and Scars after pregnancy. 3. Subject is having apparently healthy skin without any open wounds, cuts, abrasions, irritation symptoms on test area. 4. Subjects willing to give voluntary written informed consent. 5. Subjects willing to come for regular follow up visits 6. Subjects willing to avoid unnecessary sun exposure during the study period and willing to use Sun screens.

Exclusion criteria

Exclusion criteria: 1. Subjects with a history of collagen vascular disease, cutis laxica, connective tissue disease, psoriasis, or lupus. 2. Subjects diagnosed with scleroderma. 3. Subjects with any kind of skin allergy or cutaneous disease which may influence the study results. 4. Subject with any significant medical condition/ severe co-morbid disease conditions that would interfere with the participation in the trial 5. Subjects participated in any other cosmetic or therapeutic trial or in a similar investigation 6. Subjects having undergone facial treatments like bleaching or laser in last 30 days. 7. Hypersensitivity to any of the ingredients of the test product. 8. Pregnant or lactating women 9. Patients on steroid therapy or any other immunomodulatory agents.

Design outcomes

Primary

Measure	Time frame
1.Instrumental Assessment– -Mexameter (Marked scar)- pre and post study -Cutometer (Marked scar)- pre and post study 2. Vas Scar scoring 3. Skin moisture 4. Skin brightening 5. Skin smoothening Timepoint: DAy 0,DAy 30 and Day 60	—

Secondary

Measure	Time frame
Outcome TimePoints Patient and Investigator Feedbacks will be obtained Adverse event monitoringTimepoint: Screening visit, Day 0, Day 15, Day 30, Day 45, Day 60	—

Countries

India

Contacts

Public ContactDr Gayathri Sivakumar

Thirumalai medical Centre, ki3

saheerose@gmail.com9443627722

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026